You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 14, 2024

Claims for Patent: 10,369,117

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,369,117

Title:	Compositions comprising mixtures of semifluorinated alkanes
Abstract:	The invention provides novel compositions comprising at least two or more semifluorinated alkanes. The compositions can be used as medicines that are topically administered to an eye or ophthalmic tissue, such as for use in the treatment of keratoconjunctivitis sicca (dry eye) and/or meibomian gland dysfunction and symptoms associated therewith. The invention further provides kits comprising such compositions.
Inventor(s):	Günther Bernhard, Theisinger Bastian, Theisinger Sonja, Scherer Dieter
Assignee:	NOVALIQ GMBH
Application Number:	US15712053
Patent Claims:	1. A method for treating Meibomian Gland Dysfunction , comprising administering , to a patient in need thereof , a composition comprising a liquid semifluorinated alkane to the surface of the cornea and/or conjunctiva; and{'sub': 2', '6', '2', '8, 'wherein the semifluorinated alkane is F(CF)(CH)H; and'}wherein said composition is effective in spreading out over the corneal and conjunctival surface and penetrating the Meibomian gland and/or Meibomian gland ducts, and wherein said composition is effective solubilizing the abnormal Meibomian secretions of said patient.2. The method according to claim 1 , wherein said abnormal Meibomian secretions exhibit an increased viscosity and/or contain particulate cellular material.3. The method according to claim 2 , wherein said abnormal Meibomian secretions obstruct the Meibomian gland ducts.4. The method according to claim 1 , wherein said abnormal Meibomian secretions are ineffective in forming a functional stable and continuous tear film lipid layer and/or result in lipid tear film deficiency.5. The method according to claim 1 , wherein said composition is free of a therapeutically effective amount of any pharmaceutically active drug substance useful for ophthalmic treatment.6. The method according to claim 1 , wherein the patient's Meibomian Gland Dysfunction is associated with keratoconjunctivitis sicca (dry eye disease) claim 1 , or evaporative dry eye disease.7. The method according to claim 1 , wherein the composition solubilizes meibum lipids and removes abnormal and obstructive meibum from clogged Meibomian gland ducts.8. The method according to claim 1 , wherein the composition consists of F(CF)(CH)H.9. The method according to claim 1 , wherein the composition is free of any active ingredients.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.